Company news

EVE Health Group Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eve Investor Webinar - Business Update

November 5, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Change in substantial holding

October 27, 2026

Change of Director's Interest Notice

October 27, 2026

Response to ASX Price and Volume Query

October 26, 2026

Letter to Shareholders - AGM Notice of Meeting

October 15, 2026

Notice of Annual General Meeting/Proxy Form

October 15, 2026

Change of Director's Interest Notice x 3

October 4, 2026

Notification of cessation of securities - EVE

October 4, 2026

Date of AGM

September 21, 2026

Coffee Microcaps Conference Presentation

September 21, 2026

Release of Securities from Escrow

September 3, 2026

Appendix 4G and Corporate Governance Statement

August 31, 2026

Annual Report to shareholders

August 31, 2026

Appendix 4E

August 31, 2026

Quarterly Activities/Appendix 4C Cash Flow Report - Amended

August 6, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 30, 2026

Eve Initiates Pilot Clinical Study for Libbo ED Film

June 15, 2026

Appointment of Chief Executive Officer

April 27, 2026

Investor Presentation

March 25, 2026

Prospectus

March 20, 2026

EVE Placement Update

March 18, 2026

EVE Raises $0.9m to Advance Drug Reformulation Strategy

March 12, 2026

Trading Halt

March 10, 2026

EVE Advances Reformulated Drugs Targeting Global Markets

March 9, 2026

Appendix 4D and Half Year Report

February 27, 2026

Launch of Libbo and Activation of Men's Health Platform

February 9, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2026

EVE Completes Initial Production of Libbo

January 29, 2026

EVE Signs Telehealth Services Agreement with hubMed -Revised

November 19, 2025

EVE Signs Telehealth Services Agreement with hubMed

November 18, 2025

Medical Science Liaison Appointed

November 2, 2025

EVE Raises $1.1m to Accelerate Launches of Dyspro and Libbo

October 8, 2025

Dyspro Prescribed to First Patients

September 30, 2025

Eve Commences Distribution of Dyspro

September 21, 2025

Appointment of Dr Fiona Cousins to Scientific Advisory Board

September 14, 2025

Appendix 4E

August 29, 2025

Aust Regulatory Path Cleared for ED & Dysmenorrhea Products

July 20, 2025

EVE Submits First Commercial Purchase Order for Dyspro

July 6, 2025

Prescribing Agreement for ED and Dysmenorrhea Products

June 15, 2025

EVE Completes Nextract Acquisition

June 12, 2025

Results of Meeting

May 29, 2025

Notice of General Meeting/Proxy Form

April 29, 2025

Reinstatement to Quotation

April 14, 2025

EVE to Acquire Nextract, Expanding into $5.3B ED Market

April 14, 2025

Suspension from Quotation

April 4, 2025

Quarterly Activities/Appendix 5B Cash Flow Report

October 23, 2024

Preliminary Final Report

August 30, 2024

Sale of Robyndale Property (Amended)

August 30, 2024

Older news releases →

Decks

The 5 newest of 33 decks. Every deck is listed under its year.